Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction.

Abstract

The influence of glucagon-like peptide-1 has been studied in several studies in patients with acute myocardial infarction, but not in patients with non-ST-segment elevation myocardial infarction (NSTEMI). We planned to evaluate the effects of liraglutide on left ventricular function in patients with NSTEMI. A total of 90 patients were randomized 1:1 to receive either liraglutide (0.6mg for 2days, 1.2mg for 2days, followed by 1.8mg for 3days) or placebo for 7days. Eighty-three patients completed the trial. Transthoracic echocardiography was used to assess left ventricular function. At 3months, the primary endpoint, the difference in the change in left ventricular ejection fraction between the two groups was +4.7% (liraglutide vs. placebo 95% CI +0.7 to +9.2% P=0.009) under intention-to-treat analysis. The difference in decrease in serum glycosylated hemoglobin levels was -0.2% (liraglutide vs. placebo 95% CI -0.1 to -0.3%; P<0.001). Inflammation and oxidative stress improved significantly in the liraglutide group compared to the placebo group. Liraglutide could improve left ventricular function in patients with NSTEMI, making it a potential adjuvant therapy for NSTEMI.